Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Blood (2023) 142 (Supplement 1): 6534.

https://doi.org/10.1182/blood-2023-190590

Published: 2023

Journal Articles

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Blood (2023) 142 (Supplement 1): 636.

https://doi.org/10.1182/blood-2023-174750

Published: 2023

Journal Articles

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Jason Westin, Adam J. Olszewski, Laura Maria Fogliatto, Won-Seog Kim, Ho-Jin Shin, Hao Wu, Shen Yin, Song Pham, Elicia Penuel, Jing Jing, Michael C. Wei, Elizabeth L. Budde

Blood (2022) 140 (Supplement 1): 3771–3772.

https://doi.org/10.1182/blood-2022-157710

Published: 2022

Journal Articles

Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL

Marcelo Pitombeira de Lacerda, Fernanda de Morais Marques, Verena Pfister, Flavia de Carvalho Parra, Vinicius Campos de Molla, Valeria Buccheri, Rafael Dezen Gaiolla, Laura Maria Fogliatto, Rodrigo Santucci, Marcelo Bellesso, Sérgio Costa Fortier, Talita M.B. Silveira, Glaciano Ribeiro, Nelson Hamerschlak, Mihoko Yamamoto, Matheus Vescovi Goncalves, Carlos S. Chiattone, Celso Arrais-Rodrigues

Blood (2022) 140 (Supplement 1): 7041–7042.

https://doi.org/10.1182/blood-2022-170872

Published: 2022

Journal Articles

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

Blood (2022) 140 (Supplement 1): 12162–12164.

https://doi.org/10.1182/blood-2022-162516

Published: 2022

Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Blood (2021) 138 (21): 2031–2041.

https://doi.org/10.1182/blood.2020009984

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

John Kuruvilla, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, Laura Maria Fogliatto, Iara Goncalves, José de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142565

Published: 2020

Journal Articles

Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-142520

Published: 2020

Journal Articles

The Scenario of Myelofibrosis in Brazil in the View of a Panel of Experts: Challenges and Proposals

Laura Maria Fogliatto, MD PhD, Cristiana Solza, MD PhD, Alexandre Gustavo Apa, MD, Gustavo HR Magalhaes, MD MSc, Marcia Torresan Delamain, MD, Renato Tavares, MD, Lorena Lobo Figueiredo-Pontes, MD PhD

Blood (2019) 134 (Supplement_1): 5851.

https://doi.org/10.1182/blood-2019-121960

Published: 2019

Journal Articles

Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study

Renato Torrescasana Centrone, Isabel Bonafe, Eliana C Miranda, PhD, Fernanda S Seguro, MD, Gustavo HR Magalhaes, MD MSc, Nelma D Clementino, MD, Arthur Moellmann-Coelho, MD, Ingrid Luise, MD, Monika Conchon, MD, Natália N Gonçalves, MD, Jaisson Bortolini, MD, Laura Maria Fogliatto, MD PhD, Carmino Antonio Souza, MD PhD, Katia B Pagnano, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 5844.

https://doi.org/10.1182/blood-2019-127530

Published: 2019

Journal Articles

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 31.

https://doi.org/10.1182/blood-2019-128404

Published: 2019

Journal Articles

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 445.

https://doi.org/10.1182/blood-2018-99-110861

Published: 2018

Journal Articles

DA-EPOCH Was Not Better Than CHOP for Acquired Immunodeficiency Syndrome-Related Diffuse Large B Cell Lymphoma Patients Treated in a South Brazilian University Hospital

Carolina F Gomes, MD, Tito Vanelli, MD, Gueverson Rocha, Biomedical, Jeziel Basso, MD, Juliana Collman Silva, MD, Nicole Teixeira Carvalho, MD, Tatiana de Campos, MD, Harold Fabian Ibanez Torres, MD, Lucia Silla, MD PhD, Paz Aparecida Alessandra, MD, Laura Maria Fogliatto, MD

Blood (2018) 132 (Supplement 1): 5414.

https://doi.org/10.1182/blood-2018-99-117862

Published: 2018

NARROW

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL

The Scenario of Myelofibrosis in Brazil in the View of a Panel of Experts: Challenges and Proposals

Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

DA-EPOCH Was Not Better Than CHOP for Acquired Immunodeficiency Syndrome-Related Diffuse Large B Cell Lymphoma Patients Treated in a South Brazilian University Hospital

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only